Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2011

01-11-2011 | Preclinical study

Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice

Authors: Reginald M. Gorczynski, David A. Clark, Nuray Erin, Ismat Khatri

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Login to get access

Abstract

Previous studies have confirmed that levels of CD200 expression on the cells of the transplantable EMT6 mouse breast cancer line are increased markedly during growth in immunocompetent mice, unlike the persistent low levels of expression observed in NOD-SCID.IL-2γr−/− mice or mice with generalized over-expression of a CD200 transgene (CD200tg mice). Faster tumor growth occurs in both of these latter mice, with decreased evidence for a host immune reaction in lymph nodes draining the tumor (DLN). We now report evidence for a role for CD200 expression (by the host and/or tumor cells) in increased seeding of tumor cells to DLN in immunocompromised (CD200tg or NOD-SCID.IL-2γr−/−) vs immunocompetent mice, by limiting dilution cloning of tumor cells from DLN (vs contralateral lymph nodes, CLN), using control and GFP-tagged EMT6 cells. Neutralization of expressed CD200 by anti-CD200mAbs decreased the tumor metastasis at the same time as increasing detection of cytotoxic anti-tumor immune cells in DLN. Infusion of either anti-CD4 to deplete T-effector cells, or anti-TGFβ antibody, increased metastasis to DLN, as did indeed the infusion of EMT6 cells selected for the loss of TGFβRII expression. It is concluded that the increased CD200 expression by breast cancer cells (and/or host tissue) may be an important variable involved in determining the risk of metastasis.
Appendix
Available only for authorised users
Literature
1.
Geiger TR, Peeper DS (2009) Metastasis mechanisms. Biochim Biophys Acta 1796:293–308PubMed
2.
Bierie B, Moses HL (2009) Gain or loss of TGF beta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle 8:3319–3327PubMedCrossRef
3.
Pandit TS, Kennette W, MacKenzie L, Zhang GH, AlKatib W, Andrews J, Vantyghem SA, Ormond DG, Allan AL, Rodenhiser DI, Chambers AF, Tuck AB (2009) Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. Int J Oncol 35:297–308PubMed
4.
Pfeffer U, Romeo F, Noonan DM, Albini A (2009) Prediction of breast cancer metastasis by genomic profiling: where do we stand? Clin Exp Metastasis 26:547–558PubMedCrossRef
5.
DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16:91–102PubMedCrossRef
6.
Valdivia-Silva JE, Franco-Barraza J, Silva ALE, DuPont G, Soldevila G, Meza I, Garcia-Zepeda EA (2009) Effect of pro-inflammatory cytokine stimulation on human breast cancer: Implications of chemokine receptor expression in cancer metastasis. Cancer Lett 283:176–185PubMedCrossRef
7.
Pollard JW (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukocyte Biol 84:623–630PubMedCrossRef
8.
Walser TC, Ma XR, Kundu N, Dorsey R, Goloubeva O, Fulton AM (2007) Immune-mediated modulation of breast cancer growth and metastasis by the chemokine mig (CXCL9) in a murine model. J Immunother 30:490–498PubMedCrossRef
9.
Ma XR, Norsworthy K, Kundu N, Rodgers WH, Gimotty PA, Goloubeva O, Lipsky M, Li Y, Holt D, Fulton A (2009) CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 8:490–498PubMedCrossRef
10.
Takahashi M, Miyazaki H, Furihata M, Sakai H, Konakahara T, Watanabe M, Okada T (2009) Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model. Clin Exp Metastasis 26:817–828PubMedCrossRef
11.
12.
Huang B, Pan PY, Li QS, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH (2006) Gr-1(+)CD115(+) immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123–1131PubMedCrossRef
13.
Yang L, Debusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC (2004) Expansion of myeloid immune suppressor GR1+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409–421PubMedCrossRef
14.
Lee NR, Song EK, Jang KY, Choi HN, Moon WS, Kwon K, Lee JH, Yim CY, Kwak JY (2008) Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 49:247–256PubMedCrossRef
15.
Qin FXF (2009) Dynamic behavior and function of Foxp3(+) regulatory T cells in tumor bearing host. Cell Mol Immunol 6:3–13PubMedCrossRef
16.
Bierie B, Moses HL (2010) Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 21:49–59PubMedCrossRef
17.
Chen T, Jackson CR, Link A, Markey MP, Colligan BM, Douglass LE, Pemberton JO, Deddens JA, Graff JR, Carter JH (2006) Int7G24A variant of transforming growth factor-beta receptor type 1 is associated with invasive breast cancer. Clin Cancer Res 12:392–397PubMedCrossRef
18.
Yang L, Huang JH, Ren XB, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Mosesl HL (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23–35PubMedCrossRef
19.
Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck R, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL (2002) Blockade of TGFb inhibits mammary tumor cell viability, migration and metastases. J Clin Invest 109:1551–1559PubMed
20.
Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, Möhler T, De Vos J, Rossi JF, Goldschmidt H, Klein B (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108:4194–4197PubMedCrossRef
21.
Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C, Kim WY, Shields JM, Penland S, Bear JE, Thomas NE, Serody JS, Sharpless NE (2007) CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 117:3922–3929PubMed
22.
Moreaux J, Veyrune JL, Reme T, DeVos J, Klein B (2008) CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun 366:117–122PubMedCrossRef
23.
Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A (2008) Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 57:987–996PubMedCrossRef
24.
McWhirter JR, KretzRommel A, Saven A, Maruyama T, Potter KN, Mockridge CI, Ravey EP, Qin FH, Bowdish KS (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 103:1041–1046PubMedCrossRef
25.
26.
Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL (2007) Co-expression of the tolerogenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 364:778–782PubMedCrossRef
27.
Kawasaki BT, Hurt EM, Mistree T, Farrar WL (2008) Targeting cancer stem cells with phytochemicals. Mol Interv 8:174–184PubMedCrossRef
28.
Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290:1768–1771PubMedCrossRef
29.
Gorczynski RM, Chen Z, Diao J, Khatri I, Wong K, Yu K, Behnke J (2010) Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat 123:405–415PubMedCrossRef
30.
Gorczynski RM, Chen ZQ, He W, Khatri I, Sun Y, Yu K, Boudakov I (2009) Expression of a CD200 transgene is necessary for induction but not maintenance of tolerance to cardiac and skin allografts. J Immunol 183:1560–1568PubMedCrossRef
31.
Gorczynski RM (2005) CD200 and its receptors as targets for immunoregulation. Curr Opin Invest Drugs 6:483–488
32.
Gorczynski RM (2005) Thymocyte/splenocyte-derived CD4+CD25+ Treg stimulated by anti-CD200R2 derived dendritic cells suppress MLCs and skin graft rejection. Transplantation 81:1027–1034CrossRef
33.
Boudakov I, Liu J, Fan N, Gulay P, Wong K, Gorczynski RM (2007) Mice lacking CD200R1 show absence of suppression of lipopolysaccharide-induced tumor necrosis factor-alpha and mixed leukocyte culture responses by CD200. Transplantation 84:251–257PubMedCrossRef
34.
Andrews PD (2003) Aurora kinases: shining lights on the therapeutic horizon? Oncogene 24:5005–5015CrossRef
35.
Snedecor GW, Cochrane WG (1971) Statistical methods, 6th edn. Iowa State University Press, Amres, pp 135–160
36.
Kalliomaki TM, McCallum G, Wells PG, Hill RP (2009) Progression and metastasis in a transgenic mouse breast cancer model: effects of exposure to in vivo hypoxia. Cancer Lett 282:98–108PubMedCrossRef
37.
Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A (2008) Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113:1387–1395PubMedCrossRef
38.
Sica A, Allavena P, Mantovani A (2008) Cancer related inflammation: the macrophage connection. Cancer Lett 267:204–215PubMedCrossRef
39.
Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, McCarter M (2007) Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J Surg Res 141:72–77PubMedCrossRef
40.
Hilchey SP, De A, Rimsza LM, Bankert RB, Bernstein SH (2007) Follicular lymphoma intratumoral CD4(+)CD25(+)GITR(+) regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8(+)CD25(−) and CD4(+)CD25(−) T cells. J Immunol 178:4051–4061PubMed
41.
Sakaguchi S (2004) Naturally arising CD4(+) regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562PubMedCrossRef
42.
Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68:2561–2563PubMedCrossRef
43.
Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59PubMedCrossRef
44.
Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL (2009) Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest 119:1571–1582PubMedCrossRef
45.
Muraoka-Cook RS, Kurokawa H, Koh YS, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL (2004) Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 64:9002–9011PubMedCrossRef
46.
Hess MR, Freschi M, Manzo T, Jachetti E, Degl’Innocenti E, Grioni M, Basso V, Bonini C, Simpson E, Mondino A, Bellone M (2010) Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. Cancer Res 70:3505CrossRef
47.
Wong KK, Shaha S, Spaner D, Gorczynski RM (2009) Potential role for serum soluble CD200 in human Chronic Lymphocytic Leukemia. J Immunol 182:15
48.
Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S (2008) FOXP3+Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 8:57–68PubMedCrossRef
Metadata
Title
Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice
Authors
Reginald M. Gorczynski
David A. Clark
Nuray Erin
Ismat Khatri
Publication date
01-11-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1259-3

Other articles of this Issue 1/2011

Breast Cancer Research and Treatment 1/2011 Go to the issue

Brief Report

Identification of a new complex rearrangement affecting exon 20 of BRCA1

Epidemiology

Associations of objectively assessed physical activity and sedentary time with biomarkers of breast cancer risk in postmenopausal women: findings from NHANES (2003–2006)

Epidemiology

Multivitamin use and breast cancer outcomes in women with early-stage breast cancer: the Life After Cancer Epidemiology study

Epidemiology

Pathological characteristics of BRCA-associated breast cancers in Hispanics

Epidemiology

The association of reproductive factors and breastfeeding with long term survival from breast cancer

Letter to the Editor

Polymorphisms of matrix metalloproteinases (MMP) gene and breast cancer risk: appraisal of a recent meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits